BEAM — Beam Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1745999 ·
Last close
$20.65
Market Cap
$2.14B
52W High
$38.26
52W Low
$20.23
ADV30
2,017,283
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 307,000 | — | -141,322,000 | -134,405,000 | 1,269,072,000 | 213,267,000 | 316,398,000 |
| Jun 2026 | 490,000 | — | -126,553,000 | -122,678,000 | 1,386,355,000 | 219,825,000 | 318,913,000 |
| Mar 2026 | 31,738,000 | — | -107,215,000 | -94,318,000 | 1,480,798,000 | 288,291,000 | 316,360,000 |
| Dec 2025 | 114,109,000 | — | -17,445,000 | 244,297,000 | 1,481,177,000 | 294,944,000 | 242,819,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-388,646,000
Investing CF
$225,658,000
Financing CF
$108,344,000
CapEx
$-9,591,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,992,620,000
Inventory
—
Receivables
—
ST Investments
$830,606,000
EBIT TTM
$-392,535,000
Pretax Income TTM
$-107,559,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$146,644,000
EBITDA
$-370,407,008
Free Cash Flow
$-262,630,256
Enterprise Value
$1,832,278,400
Total Cash
$1,043,873,024
Total Debt
$243,872,000
Shares Out
103,495,644
Trailing EPS
$-0.87
Book Value
$9.56
ROE
-11.3%
ROA
-19.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 139,743,000 | -383,693,000 | -79,992,000 | 1,481,177,000 | 242,819,000 | 1,238,358,000 | -345,102,000 |
| Dec 2024 | 63,518,000 | -415,568,000 | -376,742,000 | 1,103,824,000 | 370,279,000 | 733,545,000 | -347,246,000 |
| Dec 2023 | 377,709,000 | -176,485,000 | -132,527,000 | 1,459,714,000 | 478,385,000 | 981,329,000 | -149,195,000 |
| Dec 2022 | 60,920,000 | -338,479,000 | -289,088,000 | 1,341,714,000 | 608,240,000 | 733,474,000 | 22,527,000 |
TTM Snapshot
Revenues TTM
$156,035,000
NetIncome TTM
$-85,427,000
OpCashFlow TTM
—
Assets (Latest)
$1,386,355,000
Forward EPS
$-4.98
Max Pain — expiry 2028-01-21
max pain strike: $22.00 · spot: $21.01 · call oi: 4,676 · put oi: 927
Expected Move to 2028-01-21:
±$12.65
(60.21%) —
implied range
$8.36 –
$33.66
· ATM straddle on $22.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS INC | $1.93B | $7.50 | — |
| REPL | Replimune Group, Inc. | $1.87B | $19.69 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.83B | $39.06 | — |
| MAZE | Maze Therapeutics, Inc. | $1.80B | $32.87 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.69B | $2.72 | — |
News headlines (Yahoo Finance, 1h cache)
Positive Trial Results Could Be A Big Moment For Beam Therapeutics (BEAM)
2026-11-18 23:21 · Yahoo
Beam Therapeutics (BEAM) Clears A Key Trial As The Undervalued Case Faces A Test
2026-11-11 00:16 · Yahoo
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
2026-11-10 17:06 · Yahoo
Beam Therapeutics to seek approval of SCD cell therapy after trial success
2026-11-10 17:05 · Yahoo
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
2026-11-10 12:00 · Yahoo
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
2026-11-04 14:00 · Yahoo
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
2026-11-03 12:15 · Yahoo
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
2026-11-03 12:00 · Yahoo
Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
2026-10-29 15:30 · Yahoo
Why Beam Therapeutics Stock Is Up 15.6% And What's Next
2026-10-29 10:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.